Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.35 |
| ▸ | LIPE | Q05469 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | ITGAV | P06756 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2512685 | 0.79 | ADAM17 (0.40) | PRMT5WDR77ITGB3ITGA2BADAM17 | |
| SCHEMBL2510033 | 0.77 | EGFR (0.43) | PRMT5WDR77ITGB3ITGA2BADAM17 | |
| SCHEMBL2509656 | 0.76 | PRMT5 (0.41) | PRMT5WDR77ITGB3ITGA2BADAM17 | |
| SCHEMBL2512573 | 0.73 | ADAM17 (0.39) | PRMT5WDR77ITGB3ITGA2BADAM17 | |
| SCHEMBL2509809 | 0.71 | PRMT5 (0.40) | PRMT5WDR77ITGB3ITGA2BADAM17 | |
| SCHEMBL23674773 | 0.71 | CYP17A1 (0.48) | — | |
| SCHEMBL2511077 | 0.71 | DRD2 (0.36) | PRMT5WDR77LIPECNR2 | |
| SCHEMBL22905666 | 0.70 | CYP17A1 (0.45) | — | |
| SCHEMBL3638127 | 0.70 | PPARD (0.36) | ITGB3ITGA2BGRM1GRM5 | |
| SCHEMBL3639868 | 0.69 | GRM1 (0.39) | ITGB3ITGA2BADAM17GRM1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664214-B2 | Small molecule potentiators of metabotropic glutamate receptors I | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-03-04 | — | — | US | disclosed |
| US-20110245232-A1 | NOVEL SMALL MOLECULE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS I | ABBOTT GMBH & CO. KG (DE) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245232-A1 | NOVEL SMALL MOLECULE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS I | GRM3, GRIN2C, GRIN2B | PRMT5 1226/4885WDR77 2121/4885ITGB3 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.